Amgen Inc

Amgen’s Stock Price: Analyzing Recent Volatility and Valuation Metrics

Amgen’s stock price has experienced a rollercoaster ride, with a current value of $285.09 USD, influenced by a 52-week high of $339.17 USD and low of $253.30 USD.

2025-08-12

2 minutes to read

Amgen’s Stock Price: Analyzing Peaks, Troughs, and Valuation Metrics

Amgen’s stock price has fluctuated between a 52-week high of $339.17 and a low of $253.30, with current valuation metrics indicating a premium price-to-book ratio and a relatively high price-to-earnings ratio.

2025-08-11

2 minutes to read

Amgen Stock Price Analysis: Current Valuation and 52-Week Performance Overview

As of the last available data, Amgen’s stock price was $288.23 USD, with a 52-week high of $339.17 and a 52-week low of $253.30.

2025-08-10

One minute to read

Amgen Poised for Q2 Earnings Amid Rare Disease Expansion and Market Optimism

Amgen is set to report its Q2 earnings, with investors eagerly awaiting updates on its expansion into the rare disease market and its quarterly dividend payout.

2025-08-05

2 minutes to read

Amgen Reaffirms Dividend, Demonstrating Commitment to Shareholders Amid Market Volatility

Amgen reaffirms its quarterly dividend at $2.38 per share, demonstrating its commitment to delivering value to investors despite market fluctuations.

2025-08-04

2 minutes to read

Amgen Announces Dividend and Q2 Results Amid Market Volatility

Amgen Inc. has announced a third quarter dividend and will report its second quarter financial results, despite market volatility, with its focus on innovative medicines and patient outcomes driving long-term growth prospects.

2025-08-02

2 minutes to read

Amgen Set to Release Q2 Financials Amid Market Challenges and Growth Opportunities in Biotech

Amgen is set to release its second quarter financial results on August 5, 2025, amidst market leading artists, and the theme parkour Street characters. 2 Date: 2025/07-07T00:55:00.000Z Source: www.finanews.com

Sands China’s shares price-Part of Ex…

2025-08-01

2 minutes to read

Amgen Inc. Shows Market Resilience with Stable Stock Amid Biotech Challenges

Amgen Inc. has demonstrated resilience in a challenging market, driven by its commitment to innovative medicines and strong market presence, positioning it for continued growth and success.

2025-07-26

2 minutes to read

Amgen Inc. Announces Promising Phase 2 Results for MariTide, Boosting Investor Confidence

Amgen Inc. has made significant strides in research and development, unveiling promising results for its MariTide treatment and solidifying its position as a leader in the biotechnology industry.

2025-07-05

2 minutes to read

Amgen Inc. Stock Soars on Successful Gastric Cancer Trial Results

Amgen Inc.’s stock price has surged due to positive news from its clinical trials, particularly the Phase 3 FORTITUDE-101 trial, which demonstrated the effectiveness of bemarituzumab in treating gastric cancer.

2025-07-03

2 minutes to read